Marcus Vale: Okay, honestly — the headline wrote itself and that's the problem.
Ben Okonkwo: Hm. Which headline specifically?
Marcus Vale: Eli Lilly's oral GLP-1 pill, orforglipron, beat oral semaglutide in a head-to-head Phase 3 trial — but the news cycle is treating AstraZeneca's elecoglipron Phase 2b data like it's equivalent evidence, and it is not.
Ben Okonkwo: Wait — are they actually running those two under the same framing, like 'two pills in the race'?
Marcus Vale: Basically, yes. And the thing is, that framing matters commercially — it flattens what Lilly actually earned against what AZ is still trying to prove.
Ben Okonkwo: So the load-bearing question is what those two trial phases actually establish — and whether the mechanism evidence from 2b even transfers to what a Phase 3 would need to show.
Marcus Vale: Eli Lilly is about to file for regulatory approval on an oral GLP-1. Phase 3 data. Orforglipron. 1.3 to 1.6% A1C reduction, 7.9% body weight at 40 weeks. That's a pivotal trial. That's a real number. And the news cycle is treating it exactly the same as AstraZeneca's elecoglipron—which is Phase 2b. Those are not the same thing.
Ben Okonkwo: Now hold on—why does that distinction matter practically? The headline numbers on elecoglipron look better. 89.6% of participants hitting the 7% HbA1c target in SOLSTICE. That's a stunning number.
Marcus Vale: It's stunning because Phase 2b trials are handpicked populations. Tight eligibility. High adherence. You strip out the guy with three comorbidities who forgets a dose every other week. Phase 3 is the messy version. Orforglipron ran ATTAIN-1—72 weeks, 11.2% weight loss, 54% of participants hitting 10% or more. That's a much harder test to pass.
Ben Okonkwo: Right, but—Vanita Aroda presented the SOLSTICE results at ADA 2026 in New Orleans and published in The Lancet the same day. That's a serious data package for Phase 2b. It's not a press release.
Marcus Vale: Totally. But The Lancet publishing a Phase 2b isn't the same as a Phase 3 approval package. AstraZeneca is buying credibility with a high-profile venue. The market is pricing elecoglipron like it's in the same lane as orforglipron, and it's not—yet.
Ben Okonkwo: Okay, but here's what I keep getting stuck on. Oral semaglutide—Novo Nordisk's 25mg Wegovy, launched January 2026—showed 13.6% mean weight loss at 64 weeks in Phase 3. That's higher than orforglipron's 7.9% at 40 weeks. Does that make oral semaglutide the winner?
Marcus Vale: No. And that's exactly the trap. 64 weeks versus 40 weeks. Different populations. You cannot compare those numbers directly. Nobody's run a head-to-head.
Ben Okonkwo: Which means the entire horse race framing—Lilly versus AstraZeneca versus Novo Nordisk—is built on incomparable data sets. These are three different experiments dressed up as a competition.
Marcus Vale: Commercially, Novo has a structural advantage though. Oral semaglutide is the same molecule as Ozempic. Insurance has already priced semaglutide. That's a different regulatory and reimbursement conversation than what Lilly is walking into with a small-molecule agonist.
Ben Okonkwo: Actually—that's the mechanistic distinction I want to flag, because it keeps getting lost. Elecoglipron and orforglipron are small molecules. Chemically synthesized, orally bioavailable by design. Oral semaglutide is a peptide that needs specialized absorption-enhancing technology just to survive your digestive system. Those are fundamentally different scientific bets. They may hit the same receptor but with very different pharmacokinetics.
Marcus Vale: Huh. Does that translate into different efficacy at scale? Or different tolerability?
Ben Okonkwo: We don't know. No cardiovascular outcomes data for any of these oral formulations. Injectable GLP-1s have some CV benefit evidence. Oral versions—nothing yet. And weight regain after cessation? Nobody's measured it for these drugs. The injectables have that story. These don't.
Marcus Vale: Here's the deal though—the access argument is real regardless. 30% of adults have needle phobia. 12% of Americans are already on a GLP-1. You pull out the needle and you expand that addressable population overnight. That's not nothing.
Ben Okonkwo: But if cost killed injectable uptake before the pill existed—and it did, Ozempic shortages, formulary fights, Wegovy access gaps—what exactly does a pill fix? The needle-phobia population is real, but it's narrower than the democratization story suggests. The 30% who won't inject aren't the same 30% who can't afford it.
Marcus Vale: That's fair—but the manufacturers are betting payers will treat an oral as a different reimbursement category. New mechanism class, different manufacturing cost structure. That's a negotiating lever.
Ben Okonkwo: What's the proof point that any payer has actually moved on that? Because the evidence I've seen says cost and insurance coverage remain unresolved for all three of these oral formulations. There's no data showing the pill breaks the access wall, only marketing suggesting it should.
Marcus Vale: No confirmed proof point. Not yet. Which means the access narrative is—
Ben Okonkwo: —aspirational. Genuinely. The mechanism works in a Phase 2b trial. The access story works in a press release. Whether small-molecule oral GLP-1s hold up in high-comorbidity, non-adherent, diverse real-world populations—the ones that were filtered out of every one of these trials—that's a 2028 question at minimum.
Ben Okonkwo: And that's the part that doesn't get written up. The signal we actually need—does the mechanism hold in the patients who were excluded—won't be visible in any approval announcement. It'll be buried in a post-market surveillance dataset that nobody reads until someone writes a NEJM letter three years from now.
Marcus Vale: By which point Lilly's already in year two of their second contract cycle and AstraZeneca's running catch-up ads. So the clinical truth lands, it just lands late. Into a market that already decided.
Ben Okonkwo: Which is either fine or a problem depending entirely on how wrong the early decision was.
